bis-isobutoxymethyl ether | 5614-27-7

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: bis-isobutoxymethyl ether
• 英文别名: α.α'-Diisobutyloxy-dimethylaether；Bis-isobutoxymethyl-aether；Bis-isobutyloxymethyl-ether；Bis(isobutoxymethyl) ether；2-methyl-1-(2-methylpropoxymethoxymethoxy)propane
• CAS: 5614-27-7
• 化学式: C₁₀H₂₂O₃
• 分子量: 190.283
• InChiKey: VKOQRHJBCQSGMC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  13
• 可旋转键数：
  8
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  27.7
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  异丁醇 、 溴(溴甲氧基)甲烷 在 sodium hydroxide 作用下， 生成 bis-isobutoxymethyl ether
  参考文献：
  名称：

  Mamedov,S.; Dzhalilov,T.N., Journal of general chemistry of the USSR, 1963, vol. 33, p. 832 - 836

  摘要：

  DOI：

文献信息

• [EN] BLOOD BRAIN BARRIER-PENETRATING OXIMES FOR CHOLISTENERASES REACTIVATION<br/>[FR] OXIMES FRANCHISSANT LA BARRIÈRE HÉMATO-ENCÉPHALIQUE POUR RÉACTIVER DES CHOLINESTÉRASES
  申请人：HUMAN BIOMOLECULAR RES INST

  公开号：WO2012083261A1

  公开（公告）日：2012-06-21

  The invention describes pharmaceutical agents capable of crossing the blood brain barrier to protect against organophosphate pesticides and nerve agents or other electrophiles by reactivating inhibited cholinesterase (i.e., acetylcholinesterase and butyrylcholinesterase) and other proteins in the peripheral and central nervous system.

  该发明描述了一种能够穿越血脑屏障的药物，可以保护免受有机磷杀虫剂、神经毒剂或其他亲电性物质的侵害，通过重新激活被抑制的胆碱酯酶（即乙酰胆碱酯酶和丁酰胆碱酯酶）以及其他蛋白质在外周和中枢神经系统中的作用。
• Preparation of polyformals
  申请人：DU PONT

  公开号：US02449469A1

  公开（公告）日：1948-09-14
• USE OF THE FL118 CORE CHEMICAL STRUCTURE PLATFORM TO GENERATE FL118 DERIVATIVES FOR TREATMENT OF HUMAN DISEASE
  申请人：Canget Biotekpharma, LLC

  公开号：EP3122754A2

  公开（公告）日：2017-02-01
• [EN] CALCIUM RECEPTOR MODULATING AGENTS<br/>[FR] AGENTS MODULATEURS DES RÉCEPTEURS DE CALCIUM
  申请人：AMGEN INC

  公开号：WO2010042642A1

  公开（公告）日：2010-04-15

  The present invention relates generally to novel calcimimetic compounds and pharmaceutical compositions comprising them. The invention also relates to methods of treating of diseases or disorders related to the function of the calcium sensing receptor using the compounds represented in Formula (I). Where Cy1 is pyridinonyl, pyridinyl, quinolinyl or 9-ethyl-9H-beta-carbolinyl, each of which optionally substituted and where Cy2 is phenyl naphthyl.
• [EN] USE OF THE FL118 CORE CHEMICAL STRUCTURE PLATFORM TO GENERATE FL118 DERIVATIVES FOR TREATMENT OF HUMAN DISEASE<br/>[FR] UTILISATION DE LA PLATE-FORME STRUCTURALE CHIMIQUE CENTRALE DE FL118 POUR PRODUIRE DES DÉRIVÉS DE FL118 POUR LE TRAITEMENT D'UNE MALADIE HUMAINE
  申请人：CANGET BIOTEKPHARMA LLC

  公开号：WO2015148415A2

  公开（公告）日：2015-10-01

  Described herein, are FLl18 core structure platform compounds, matter of compositions, formulation, methods and uses for treating cancer or other human diseases. Chemical modifications of the FLl18 structure are employed alone or in combination with other anti-cancer agents to preclude or reverse refractory cancer phenotypes and for unique personalized cancer treatment (personalized medicine or as Obama called precision medicine) through application of a series of structural relevant individual FLl18 platform-derived analogues.